What are ASCO/OH(CCO) recommendations for treating stage IV non–small cell lung cancer (NSCLC) in patients with NTRK fusions?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

See the list below:

  • For first-line therapy, entrectinib or larotrectinib or standard treatment for NSCLC without driver mutations may be offered.
  • For second-line therapy in patients who received NTRK-targeted therapy in the first-line setting, standard treatment for NSCLC without driver mutations may be offered.
  • For second-line therapy in patients who did not receive NTRK-targeted therapy in the first-line setting, entrectinib or larotrectinib may be offered.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!